Cancer and Leukemia Group B - The Ohio State University

描述（由申请人提供）：本补助金的目的是通过为俄亥俄州州立大学（OSU）的CALGB计划提供必要的基础设施，支持癌症和白血病组B（CALGB）的科学和临床活动。俄勒冈州立大学的多学科合作研究方法提供了更有效的预防，检测和治疗成人癌症的方法，特别关注乳腺癌，胃肠癌，泌尿生殖系统恶性肿瘤，血液系统恶性肿瘤，肺癌和黑色素瘤。这项研究集中了医学和血液肿瘤学家、外科医生、放射治疗师、移植师、精神病学家、病理学家、细胞遗传学家、转化实验室科学家、基础科学家、统计学家、流行病学家、护士、药剂师、和临床研究助理，精心设计和进行研究，提出相互关联的临床和基础科学问题，这些问题的答案对患者护理和减少癌症有重大贡献在高危人群中。该项目包括：1）在I、II和III期临床试验中探索新的治疗剂及其相关毒性; 2）评估新方案的功效和毒性，包括新药物和旧药物的组合，以更有效地利用协同组合; 3）开发针对特定肿瘤问题的多模式方法，以最佳组合使用手术、免疫学和放射学措施; 4）相关的基础科学学科，如分子遗传学、生物化学、药理学、免疫学和生物统计学参与特定治疗方案的制定和执行; 5）通过使用这些协议来教育博士生和博士后学生、护士、专职医疗人员和医生，改善社区的癌症护理，6）评估与临床终点相关的生物学研究，以制定更合理的癌症管理，7）评估癌症控制工作，如早期发现，以及8）研究癌症的心理社会方面。在Clara D.布卢姆菲尔德，医学博士，俄勒冈州立大学通过患者参与方案，制定和领导研究方案，领导和参与CALGB的科学和行政委员会，多个CALGB核心实验室和设施的住房，CALGB会议参与和集团出版物的作者身份，为CALGB活动做出贡献。此外，俄勒冈州立大学进行机构试点，并提供实验室数据，导致新的CALGB研究。对这一计划的支持将提高我们预防、检测、治疗和治愈成人癌症的能力，并提高癌症幸存者的生活质量。

DESCRIPTION (provided by applicant): The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multidisciplinary collaborative research approach at OSU has a tract record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast cancer, gastrointestinal cancers, genitourinary malignancies, hematologic malignancies, lung cancer and melanoma. This research focuses the efforts of medical and hematologic oncologists, surgeons, radiotherapists, transplanters, psychiatrists, pathologists, cytogeneticists, translational laboratory scientists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk. Included in this project are: 1) the exploration of new therapeutic agents, and their associated toxicities, in Phase I, II and III clinical trials; 2) the evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology and biostatistics in the formulation and execution of specific therapy protocols; 5) the improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) the evaluation of biologic studies in correlation with clinical endpoint to develop more rationally based cancer management, 7) the evaluation of cancer controls efforts such as early detection, and 8) the study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core laboratories and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors.